168 reports of this reaction
1.5% of all KETAMINE HYDROCHLORIDE reports
#16 most reported adverse reaction
HYPERHIDROSIS is the #16 most commonly reported adverse reaction for KETAMINE HYDROCHLORIDE, manufactured by Par Health USA, LLC. There are 168 FDA adverse event reports linking KETAMINE HYDROCHLORIDE to HYPERHIDROSIS. This represents approximately 1.5% of all 11,206 adverse event reports for this drug.
Patients taking KETAMINE HYDROCHLORIDE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for KETAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for KETAMINE HYDROCHLORIDE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 168 FDA reports for KETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.5% of all adverse event reports for KETAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience hyperhidrosis while taking KETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.